Influenza A
Conditions
Keywords
Influenza A
Brief summary
The purpose of this study is to evaluate the antiviral effect, as measured by viral titer in nasal secretions in adults with acute uncomplicated seasonal influenza A following administration of VX-787.
Interventions
DRUGVX-787 300 mg
A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
DRUGVX-787 600 mg
A oral dose of VX-787 600 mg (formulated as 2\*300 mg tablets) will be administered over 5-6 days.
A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
DRUGPlacebo
Subjects will receive matching placebo of Oseltamivir
Sponsors
Janssen Pharmaceuticals
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
Part A 1. Willing and able to comply with the NP swab procedure 2. Subject will sign and date an informed consent form (ICF) 3. Presenting to the clinic with symptoms suggestive of a diagnosis of acute influenza. Symptoms include oral temperature ≥38°C (100.4°F) within the prior 24 hours, at least 1 respiratory symptom AND at least 1 systemic symptom. 4. Understand that no study treatment will be provided to subjects in Part A but that they are free to receive any treatment considered appropriate by their physician Part B 1. Willing and able to comply with study requirements including treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures 2. Subject will sign and date an ICF 3. Present to the clinic with symptoms suggestive of a diagnosis of acute influenza. Symptoms include documented oral temperature ≥38°C (100.4°F) any time during the screening process, at least 1 respiratory symptom AND at least 1 systemic symptom, both scored as at least moderate. 4. The time of onset of flu-like symptoms to the time anticipated for the start of treatment must be ≤48 hours. Onset of symptoms is defined as the first time (within 1 hour) the subject becomes aware of respiratory or systemic symptoms compatible with the flu or experiences an oral temperature ≥38°C (100.4°F) 5. Positive Rapid Influenza Diagnostic Test for influenza type A 6. Body mass index (BMI) of 18.0 to 33.0 kg/m2, inclusive, and a total body weight \>50 kg
Exclusion criteria
Part B 1. History of any illness or any clinical condition that, in the opinion of the investigator or the subject's general practitioner, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject. 2. Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy, or other gastrointestinal tract surgery, except appendectomy). 3. Immunized (intranasal or injected vaccine) against influenza in the 6 months before study entry. 4. At Screening, an ECG that is abnormal and deemed by the investigator(s) to be clinically significant. 5. For female subjects: Pregnant or nursing subjects and female subjects of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol. 6. For male subjects, unwilling to comply with contraception requirements as outlined in the study protocol. 7. Blood donation (of approximately 1 pint \[500 mL\] or more) within 56 days before the first study drug dose. 8. Use of the following medications: * Influenza antiviral medication (oseltamivir, zanamivir, rimantidine, or amantadine) within 14 days or ribavirin within 6 months of screening. * Substrates of OATP1B1 and/or OATP1B3, including atrasentan, bosentan, ezetimibe, glyburide, irinotecan, repaglinide, rifampin, telmisartan, valsartan, and olmesartan, from Day 1 through the last dose of study drug. Statins (i.e., HMG CoA reductase inhibitors) may be continued, but subjects should be cautioned and observed for potential statin-related toxicity. Alternatively, subjects can abstain from statins for the duration of study drug dosing. * Strong inhibitors or inducers of CYP3A metabolism, including carbamazepine, clarithromycin, HIV and HCV protease inhibitors, itraconazole, ketoconazole, nefazodone, phenytoin, posaconazole, rifampin, St. John's wort, telithromycin, and voriconazole from 2 weeks prior to the first dose of study drug until the last PK sample is collected on Day 8. * An investigational drug or device 30 days before the first dose of study drug, 5 half lives before the first dose of study drug, or time determined by local requirements, whichever is longest. 9. History of excessive alcohol consumption. 10. History of known or current usage of drugs of abuse. 11. Hospitalized subjects and subjects with bacterial infections requiring systemic antibacterial agents at the time of screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area under the curve (AUC) of the log10 Nasal Viral Load on Day 8 | Day 8 | Area under the curve (AUC) of the log10 nasal viral load is measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability based on assessment of adverse events, clinical laboratory assessments, 12-lead electrocardiograms (ECGs), and vital signs | Day 14 | — |
| Antiviral effect and viral kinetics composite | Days 1 - 8 | Antiviral effect and viral kinetics in relation to: * Duration of viral shedding in nasal secretions by qRT-PCR and viral culture * AUC of the log10 viral load measured by viral culture * Peak viral shedding titer by qRT-PCR and viral culture. |
| Time to Resolution of Influenza Symptoms After Initiation of Study Drug | Baseline up to Day 14 | Estimated acceleration factors expressed as the ratio of the time to resolution of influenza symptoms as compared to placebo time to negativity. Resolution of influenza symptoms was the time of the first of 3 evaluations (over 24 hours) in which all symptom scores for each of the 3 assessments are 0 or 1 for all 7 primary influenza symptoms (cough, sore throat, headache, nasal stuffiness, feverishness or chills, muscle or joint pain, and fatigue) of the Flu-iiQ\^TM. The Flu-iiQ\^TM questionnaire consists of 4 modules, including 1 module assessing influenza symptoms, 1 module assessing the impact of influenza on normal functioning, and 2 modules assessing the impact of influenza on the subject's emotional state. The Influenza Symptom assessment (Module 1) is scored on a 4 point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe) for each of 10 influenza symptoms. |
| Pharmacokinetic parameters of VX787, as determined by population analysis | Day 14 | A population Pharmacokinetic Pharmacodynamic analysis of plasma concentration data of VX-787 will be performed using the nonlinear mixed effects modeling approach. |
| Viral sequence analysis to monitor for emergence of viral variants resistant to VX 787 and to oseltamivir | Day 14 | — |
| Clinical composite symptom scores | Day 14 | Clinical symptom scores * Composite symptom score AUC * Time to peak of composite symptom score, * Duration and time to resolution of composite symptom score from peak |
Countries
Belgium, Bulgaria, Canada, Estonia, Germany, Latvia, Puerto Rico, South Africa, United States
Outcome results
None listed